CTOs on the Move

Intermountain Therapy Animals

www.therapyanimals.org

 
Intermountain Therapy Animals is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Community Products

Community Products is a Rifton, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AmMed Direct

AmMed Direct is a Antioch, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Artio Medical

ARTIO MEDICAL, formerly known as Metactive Medical, is developing innovative endovascular medical devices with the potential to provide immediate and lasting occlusion of aneurysms, blood vessels, and other vascular structures. Artio`s products enable precision placement and provide immediate, complete, and lasting occlusion of target vessel segments and saccular aneurysms. These products will enable physicians to perform better, faster, and safer vascular occlusion procedures.

DURECT Corporation

DURECT Corporation is a Cupertino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

www.biosig.com

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.